Anthony Natale
Venture Partner @ Prism Venture Management
Anthony Natale is a startup investor at Prism Venture Management. Tony Natale, M.D. blends his extensive business, investment and company formation experience with a background in clinical medicine. Dr. Natale has invested across a number of therapeutic areas, including orthopedics, ENT, ophthalmology, GI, minimally invasive technologies, robotics and women’s health. A committed board member, Dr. Natale worksalongside entrepreneurs to build out management teams, establish effective corporate governance and bring operational discipline to R&D and early commercialization efforts. Dr. Natale was previously with Prism Ventures and MDS Capital where he made and managed investments in the medical technology sector. He has been a founder, director and/or lead investor of several venture-backed life sciences companies, including Mako Surgical. Dr. Natale trained in General Surgery and Otolaryngology/Head and Neck Surgery at the University of Connecticut and Hartford Hospital and held clinical appointments in Hartford area hospitals before transitioning into entrepreneurial activities. He holds a B.A., Phi Beta Kappa, from the University of Virginia, an M.D. from the University of Florida College of Medicine and an M.B.A. from Yale University’s School of Management.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $8M / Series A / Jan 31, 2008 |
Co-Investors
About Prism Venture Management
Prism Ventureworks has 5 funds with $1.25 billion in investments. Their most recent fund is for $250M which was raised in June 2005.Each of their team members focuses on different industry sectors within technology and life sciences. These industry sectors in technology include the digital living, wireless, mobile and telecommunicationsmarkets, as well as promising opportunities in next-generation data centers and on-demand and security applications. In life sciences, we focus on medical devices, therapeutics and breakthrough diagnostics.
Prism Venture Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Anthony Natale
Venture Partner
|
|||
Bong Koh
Team Member
|
|||
|
Duane Mason
Co-founder and General Partner
|
|||
James Counihan
General Partner and Managing Director
|
|||
|
Jim Counihan
General Partner & Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
When did Anthony Natale last invest?
The most recent investment recorded for Anthony Natale closed in Jan 2008. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
